Market news

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026. On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle,

Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) Current cash runway expected into the

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD) shares moved

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).